CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Respiratory physiotherapyWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1346 Linagliptin 5 MG Wiki 1.00

Correlated MeSH Terms (8)


Name (Synonyms) Correlation
D008659 Metabolic Diseases NIH 1.00
D004700 Endocrine System Diseases NIH 1.00
D044882 Glucose Metabolism Disorders NIH 1.00
D003924 Diabetes Mellitus, Type 2 NIH 0.41
D003920 Diabetes Mellitus, NIH 0.32
D012140 Respiratory Tract Diseases NIH 0.24
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (3)


Name (Synonyms) Correlation
HP:0000818 Abnormality of the endocrine system HPO 1.00
HP:0005978 Type II diabetes mellitus HPO 0.41
HP:0000819 Diabetes mellitus HPO 0.32

There is one clinical trial.

Clinical Trials


1 Monocentric, Observational, Retrospective Study on Respiratory Physiotherapy in Severe COVID-19 Patients: the FTR-COVID Study.

COVID-19 is an infectious disease caused by SARS-CoV2 virus. COVID-19 patients can develop a severe disease that can lead to hypoxic respiratory failure and acute respiratory distress syndrome (ARDS). Severe patients can require access to intensive care unit (ICU). Early rehabilitation is known to be effective in critically ill patients and in ARDS. The role of respiratory physiotherapy in critical COVID-19 patients is still unclear. The aim of this study is to describe the bundle and the timing of respiratory physiotherapy used with severe COVID-19 patients from ICU to hospital discharge. Functional condition of patients at discharge will be assessed and described.

NCT04459819 COVID-19 Other: Respiratory physiotherapy

Primary Outcomes

Description: Total number of physiotherapy treatments performed on patients during hospitalization

Measure: Number of physiotherapy treatments

Time: Through study completion, an average of 60 days

Description: Number of each activity performed on patients among early mobilization, positioning, Uso of non invasive ventilation (NIV) and/or continuous positive airway pressure (CPAP), oxygen titration, airway clearance.

Measure: Type of physiotherapy treatments

Time: Through study completion, an average of 60 days

Description: Median number of days from patients intubation to the first physiotherapy treatment

Measure: Time of the first physiotherapy treatment

Time: From patient intubation to first time patient was treated by a physiotherapist; up to 60 days

Secondary Outcomes

Description: Median number of days from patients intubation to standing

Measure: First time standing

Time: From patient intubation to first time standing; up to 60 days

Description: Median number of days from patients intubation to walking

Measure: First time walking

Time: From patient intubation to first time walking; up to 60 days

Description: Median number of days from patients intubation to sitting out of bed

Measure: First time sitting out of bed

Time: From patient intubation to first time sitting out of bed; up to 60 days

Description: Median distance (metres) obtained at the 6MWT

Measure: 6 minutes walking test (6MWT)

Time: Assessed when patients are discharged from the hospital; up to 60 days

Description: Median number of sit-to-stand repetitions obtained

Measure: 1 minute sit-to-stand test (1m-STST)

Time: Assessed when patients are discharged from the hospital; up to 60 days

Description: Median upper extremity muscle strength measured by the Medical Research Council sum score (MRC-SS). The muscle scale grades muscle power on a scale of 0 (no visible muscle contraction) to 5 (active movement against full resistance). The movement tested are wrist flexion, forearm flexion and shoulder abduction.

Measure: Upper extremity muscles strength

Time: Assessed at 2 time points, when patients are discharged from ICU and when patients are discharged from the hospital; up to 60 days.

Description: Median lower extremity muscle strength measured by the Medical Research Council sum score (MRC-SS). The muscle scale grades muscle power on a scale of 0 (no visible muscle contraction) to 5 (active movement against full resistance). The movement tested are ankle dorsiflexion, knee extension and hip flexion.

Measure: Lower extremity muscles strength

Time: Assessed at 2 time points, when patients are discharged from ICU and when patients are discharged from the hospital; up to 60 days.

Description: Median score obtained th the Barthel Index for Activities of Daily Living (ADL). The Barthel Index measures functional independence in ADL. Scores range from 0 to 100, with higher scores indicating greater independence in ADL.

Measure: Functional independence in ADL

Time: Assessed when the patient is discharged from the hospital; up to 60 days.

Description: Mean number of days patients stayed in ICU

Measure: ICU stay length

Time: From ICU admission to ICU discharge; up to 60 days.

Description: Mean number of days patients stayed at the hospital

Measure: Length of hospitalization

Time: From hospital admission to hospital discharge; up to 60 days.

Description: Mean number of days patients were invasively mechanically ventilated

Measure: Duration of invasive mechanical ventilation (IMV)

Time: From first day patient are mechanically ventilated to IMV stop; up to 60 days.

Description: Number of patients that following hospital discharge returned home

Measure: Patients returned home

Time: Up to 60 days.

Description: Number of patients that were discharged from acute hospital to in-patient rehabilitation

Measure: Patients discharged to in-patient rehabilitation

Time: Up to 60 days.

Description: Number of patients that following hospital discharge were transferred to other hospitals

Measure: Patients transferred to other hospitals

Time: Up to 60 days.

Description: Number of patients that died from any cause during hospitalization

Measure: Exitus

Time: From ICU admission until date of death from any cause, assessed up to 60 days.


No related HPO nodes (Using clinical trials)